Thrombin generation in patients with cirrhosis: The role of platelets

Armando Tripodi, Massimo Primignani, Veena Chantarangkul, Marigrazia Clerici, Alessandra Dell'Era, Federica Fabris, Francesco Salerno, Pier Mannuccio Mannucci

Research output: Contribution to journalArticle

231 Citations (Scopus)

Abstract

Coagulation factor defects, thrombocytopenia, and thrombocytopathy are associated with cirrhosis. However, bleeding in patients who have cirrhosis does not entirely correlate with abnormal coagulation tests. Recently, it was shown that because of the concomitant abnormalities of the procoagulant and anticoagulant drives, thrombin generation in plasma patients with cirrhosis is normal when assessed with assays that include thrombomodulin (the main protein C activator). However, thrombin is also generated in vivo as a function of platelets, suggesting that thrombocytopenia and thrombocytopathy might affect thrombin generation in patients with cirrhosis. We addressed this issue using an assay that accounts for the contribution of plasma and platelets. The study showed that platelet-rich plasma with platelets adjusted by dilution of autologous platelet-rich into autologous platelet-poor plasma to a standard count (100 × 10 9/L) generates as much thrombin in patients with cirrhosis as in controls (1,063 nmol/L vs. 1,167 nmol/L; P value not significant). When platelets were adjusted to correspond to whole-blood counts, patients with cirrhosis generated significantly less thrombin than controls (949 nmol/L vs. 1,239 nmol/L; P <.001). Furthermore, thrombin generation correlated with platelet numbers (p = 0.50; P <.001). In addition, the amount of thrombin generated as a function of the whole-blood patients' platelet counts increased significantly when the numbers were adjusted to 100 × 10 9/L (953 nmol/L vs. 1,063 nmol/L; P <.001). In conclusion, severe thrombocytopenia may limit thrombin generation in patients with cirrhosis. These findings might justify platelet transfusion in patients with low platelet counts when they bleed spontaneously or before undergoing surgery or liver biopsy. Controlled clinical trials supporting this indication are warranted.

Original languageEnglish
Pages (from-to)440-445
Number of pages6
JournalHepatology
Volume44
Issue number2
DOIs
Publication statusPublished - Aug 2006

Fingerprint

Thrombin
Fibrosis
Blood Platelets
Blood Platelet Disorders
Platelet Count
Thrombocytopenia
Thrombomodulin
Platelet Transfusion
Platelet-Rich Plasma
Blood Coagulation Factors
Controlled Clinical Trials
Protein C
Anticoagulants
Hemorrhage
Biopsy
Liver

ASJC Scopus subject areas

  • Hepatology

Cite this

Thrombin generation in patients with cirrhosis : The role of platelets. / Tripodi, Armando; Primignani, Massimo; Chantarangkul, Veena; Clerici, Marigrazia; Dell&apos;Era, Alessandra; Fabris, Federica; Salerno, Francesco; Mannucci, Pier Mannuccio.

In: Hepatology, Vol. 44, No. 2, 08.2006, p. 440-445.

Research output: Contribution to journalArticle

Tripodi, Armando ; Primignani, Massimo ; Chantarangkul, Veena ; Clerici, Marigrazia ; Dell&apos;Era, Alessandra ; Fabris, Federica ; Salerno, Francesco ; Mannucci, Pier Mannuccio. / Thrombin generation in patients with cirrhosis : The role of platelets. In: Hepatology. 2006 ; Vol. 44, No. 2. pp. 440-445.
@article{7ea17968e757454285d7b6f997117e02,
title = "Thrombin generation in patients with cirrhosis: The role of platelets",
abstract = "Coagulation factor defects, thrombocytopenia, and thrombocytopathy are associated with cirrhosis. However, bleeding in patients who have cirrhosis does not entirely correlate with abnormal coagulation tests. Recently, it was shown that because of the concomitant abnormalities of the procoagulant and anticoagulant drives, thrombin generation in plasma patients with cirrhosis is normal when assessed with assays that include thrombomodulin (the main protein C activator). However, thrombin is also generated in vivo as a function of platelets, suggesting that thrombocytopenia and thrombocytopathy might affect thrombin generation in patients with cirrhosis. We addressed this issue using an assay that accounts for the contribution of plasma and platelets. The study showed that platelet-rich plasma with platelets adjusted by dilution of autologous platelet-rich into autologous platelet-poor plasma to a standard count (100 × 10 9/L) generates as much thrombin in patients with cirrhosis as in controls (1,063 nmol/L vs. 1,167 nmol/L; P value not significant). When platelets were adjusted to correspond to whole-blood counts, patients with cirrhosis generated significantly less thrombin than controls (949 nmol/L vs. 1,239 nmol/L; P <.001). Furthermore, thrombin generation correlated with platelet numbers (p = 0.50; P <.001). In addition, the amount of thrombin generated as a function of the whole-blood patients' platelet counts increased significantly when the numbers were adjusted to 100 × 10 9/L (953 nmol/L vs. 1,063 nmol/L; P <.001). In conclusion, severe thrombocytopenia may limit thrombin generation in patients with cirrhosis. These findings might justify platelet transfusion in patients with low platelet counts when they bleed spontaneously or before undergoing surgery or liver biopsy. Controlled clinical trials supporting this indication are warranted.",
author = "Armando Tripodi and Massimo Primignani and Veena Chantarangkul and Marigrazia Clerici and Alessandra Dell&apos;Era and Federica Fabris and Francesco Salerno and Mannucci, {Pier Mannuccio}",
year = "2006",
month = "8",
doi = "10.1002/hep.21266",
language = "English",
volume = "44",
pages = "440--445",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Thrombin generation in patients with cirrhosis

T2 - The role of platelets

AU - Tripodi, Armando

AU - Primignani, Massimo

AU - Chantarangkul, Veena

AU - Clerici, Marigrazia

AU - Dell&apos;Era, Alessandra

AU - Fabris, Federica

AU - Salerno, Francesco

AU - Mannucci, Pier Mannuccio

PY - 2006/8

Y1 - 2006/8

N2 - Coagulation factor defects, thrombocytopenia, and thrombocytopathy are associated with cirrhosis. However, bleeding in patients who have cirrhosis does not entirely correlate with abnormal coagulation tests. Recently, it was shown that because of the concomitant abnormalities of the procoagulant and anticoagulant drives, thrombin generation in plasma patients with cirrhosis is normal when assessed with assays that include thrombomodulin (the main protein C activator). However, thrombin is also generated in vivo as a function of platelets, suggesting that thrombocytopenia and thrombocytopathy might affect thrombin generation in patients with cirrhosis. We addressed this issue using an assay that accounts for the contribution of plasma and platelets. The study showed that platelet-rich plasma with platelets adjusted by dilution of autologous platelet-rich into autologous platelet-poor plasma to a standard count (100 × 10 9/L) generates as much thrombin in patients with cirrhosis as in controls (1,063 nmol/L vs. 1,167 nmol/L; P value not significant). When platelets were adjusted to correspond to whole-blood counts, patients with cirrhosis generated significantly less thrombin than controls (949 nmol/L vs. 1,239 nmol/L; P <.001). Furthermore, thrombin generation correlated with platelet numbers (p = 0.50; P <.001). In addition, the amount of thrombin generated as a function of the whole-blood patients' platelet counts increased significantly when the numbers were adjusted to 100 × 10 9/L (953 nmol/L vs. 1,063 nmol/L; P <.001). In conclusion, severe thrombocytopenia may limit thrombin generation in patients with cirrhosis. These findings might justify platelet transfusion in patients with low platelet counts when they bleed spontaneously or before undergoing surgery or liver biopsy. Controlled clinical trials supporting this indication are warranted.

AB - Coagulation factor defects, thrombocytopenia, and thrombocytopathy are associated with cirrhosis. However, bleeding in patients who have cirrhosis does not entirely correlate with abnormal coagulation tests. Recently, it was shown that because of the concomitant abnormalities of the procoagulant and anticoagulant drives, thrombin generation in plasma patients with cirrhosis is normal when assessed with assays that include thrombomodulin (the main protein C activator). However, thrombin is also generated in vivo as a function of platelets, suggesting that thrombocytopenia and thrombocytopathy might affect thrombin generation in patients with cirrhosis. We addressed this issue using an assay that accounts for the contribution of plasma and platelets. The study showed that platelet-rich plasma with platelets adjusted by dilution of autologous platelet-rich into autologous platelet-poor plasma to a standard count (100 × 10 9/L) generates as much thrombin in patients with cirrhosis as in controls (1,063 nmol/L vs. 1,167 nmol/L; P value not significant). When platelets were adjusted to correspond to whole-blood counts, patients with cirrhosis generated significantly less thrombin than controls (949 nmol/L vs. 1,239 nmol/L; P <.001). Furthermore, thrombin generation correlated with platelet numbers (p = 0.50; P <.001). In addition, the amount of thrombin generated as a function of the whole-blood patients' platelet counts increased significantly when the numbers were adjusted to 100 × 10 9/L (953 nmol/L vs. 1,063 nmol/L; P <.001). In conclusion, severe thrombocytopenia may limit thrombin generation in patients with cirrhosis. These findings might justify platelet transfusion in patients with low platelet counts when they bleed spontaneously or before undergoing surgery or liver biopsy. Controlled clinical trials supporting this indication are warranted.

UR - http://www.scopus.com/inward/record.url?scp=33747058510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747058510&partnerID=8YFLogxK

U2 - 10.1002/hep.21266

DO - 10.1002/hep.21266

M3 - Article

C2 - 16871542

AN - SCOPUS:33747058510

VL - 44

SP - 440

EP - 445

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 2

ER -